EMERGING-CTONG 1103 was a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib vs. GC chemotherapy as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 non-small cell lung cancer with EGFR mutations in exon 19 or 21 (10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.